MCID: HDG006
MIFTS: 22

Hodgkin's Paragranuloma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Hodgkin's Paragranuloma

MalaCards integrated aliases for Hodgkin's Paragranuloma:

Name: Hodgkin's Paragranuloma 12 15
Hodgkin Paragranuloma 12
Hodgkin Disease 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8642
UMLS 71 C0019829

Summaries for Hodgkin's Paragranuloma

MalaCards based summary : Hodgkin's Paragranuloma, also known as hodgkin paragranuloma, is related to lymphoma and pneumonia. An important gene associated with Hodgkin's Paragranuloma is UCHL1 (Ubiquitin C-Terminal Hydrolase L1). The drugs Etoposide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone.

Related Diseases for Hodgkin's Paragranuloma

Diseases related to Hodgkin's Paragranuloma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 lymphoma 10.1
2 pneumonia 10.1
3 orbit lymphoma 10.1
4 orbital lymphoma 10.1

Symptoms & Phenotypes for Hodgkin's Paragranuloma

Drugs & Therapeutics for Hodgkin's Paragranuloma

Drugs for Hodgkin's Paragranuloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 352)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4 33419-42-0 36462
2
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
3
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Epirubicin Approved Phase 4 56420-45-2 41867
9
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
10 Gastrointestinal Agents Phase 4
11 Hormones Phase 4
12 Antiemetics Phase 4
13 Hormone Antagonists Phase 4
14 glucocorticoids Phase 4
15 Anti-Inflammatory Agents Phase 4
16 Etoposide phosphate Phase 4
17 Methylprednisolone Acetate Phase 4
18 Protective Agents Phase 4
19 Neuroprotective Agents Phase 4
20
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
21
Panobinostat Approved, Investigational Phase 3 404950-80-7 6918837
22
Ichthammol Approved Phase 3 8029-68-3
23
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
24
Chlorambucil Approved Phase 3 305-03-3 2708
25
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560 441411
26
Aldesleukin Approved Phase 2, Phase 3 85898-30-2, 110942-02-4
27
Daunorubicin Approved Phase 3 20830-81-3 30323
28
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
29
rituximab Approved Phase 3 174722-31-7 10201696
30
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
31
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
34
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
35
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
36
Vinblastine Approved Phase 3 865-21-4 241903 13342
37
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
38
Melphalan Approved Phase 3 148-82-3 460612 4053
39
Gemcitabine Approved Phase 3 95058-81-4 60750
40
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
41
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
42
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
43
Ifosfamide Approved Phase 3 3778-73-2 3690
44
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
45
Cortisone Experimental Phase 3 53-06-5 222786
46
Mitoguazone Investigational Phase 3 459-86-9
47 Hematinics Phase 3
48 Epoetin alfa Phase 3 113427-24-0
49 Norgestimate, ethinyl estradiol drug combination Phase 3
50 Fluorodeoxyglucose F18 Phase 3

Interventional clinical trials:

(show top 50) (show all 703)
# Name Status NCT ID Phase Drugs
1 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
2 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
3 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
4 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
5 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Active, not recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
6 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
7 Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease Unknown status NCT00002462 Phase 3 doxorubicin hydrochloride;mechlorethamine hydrochloride;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
8 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
9 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
10 BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma Unknown status NCT00049595 Phase 3 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
11 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
12 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma Unknown status NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
13 Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) Completed NCT00443677 Phase 3 COPPEBVCAD vs BEACOPP vs ABVD
14 Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3 Filgrastim SD/01;Adriamycin;Bleomycin;Vinblastine;DTIC
15 HD12 for Advanced Stages Completed NCT00265031 Phase 3 Cyclophosphamide;Adriamycin;Etoposide;Procarbazine;Prednisone;Vincristine;Bleomycin
16 HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma Completed NCT01356680 Phase 3 BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone);ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
17 HD10 for Early Stages Completed NCT00265018 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC
18 HD11 for Intermediate Stages Completed NCT00264953 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC;Etoposide;Procarbazine;Prednisone;Vincristine
19 Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed NCT00398411 Phase 3 moxifloxacin;placebo
20 A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment Completed NCT01854567 Phase 3
21 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy Completed NCT00039910 Phase 3 (PN-152,243)/ PN-196,444
22 A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
23 Randomized Phase III Study of a Treatment Driven by Early PET Response Compared to a Treatment Not Monitored by Early PET in Patients With Ann Arbor Stage III-IV or High Risk IIB Hodgkin Lymphoma Completed NCT01358747 Phase 3 BEACOPPesc;BEACOPPesc - ABVD - PET2
24 Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3 lenograstim
25 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT) Completed NCT01034163 Phase 3 Panobinostat;Placebo
26 A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease Completed NCT00302003 Phase 3 doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine
27 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed NCT01188798 Phase 3 Methotrexate;Pentostatin
28 Randomized Trial of Subtotal Nodal Irradiation Versus Doxorubicin, Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease Completed NCT00002495 Phase 3 doxorubicin hydrochloride;vinblastine
29 Early Salvage With High Dose Chemotherapy and Stem Cell Transplantation in Advanced Stage Hodgkin's Lymphoma Patients With Positive PET After Two Courses of ABVD (PET-2 Positive) and Comparison of RT Versus no RT in PET-2 Negative Patients Completed NCT00784537 Phase 2, Phase 3 ABVD;ABVD and Radiotherapy
30 Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study Completed NCT00005578 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
31 A UKLG Randomised Trial of Initial Chemotherapy for Advanced Stage Hodgkins Disease Completed NCT00003421 Phase 3 ABVD regimen;chlorambucil;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
32 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
33 Plerixafor and G−CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non−Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) − Safety Study in a General Autologous Transplant Population Completed NCT00838357 Phase 3 Generic = Plerixafor
34 Prospective Randomized Comparison of ABVD Versus BEACOPP Chemotherapy With or Without Radiotherapy for Advanced Stage or Unfavorable Hodgkin's Lymphoma (HL) Completed NCT01251107 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
35 RESPONSE DEPENDENT TREATMENT OF STAGES IA, IIA AND IIIA HODGKIN'S DISEASE WITH DBVE AND LOW DOSE INVOLVED FIELD IRRADIATION WITH OR WITHOUT ZINECARD: A PEDIATRIC ONCOLOGY GROUP PHASE III STUDY Completed NCT00002827 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;vincristine sulfate
36 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) on Anemia and Quality of Life in Children With Cancer Undergoing Myelosuppressive Chemotherapy Completed NCT00261677 Phase 3 epoetin alfa
37 A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3 StemEx®
38 The H10 EORTC/GELA/IIL Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic Stage I/II Hodgkin's Lymphoma Completed NCT00433433 Phase 3 ABVD q4 weeks;BEACOPP escalated q3 weeks
39 A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy Versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
40 A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease Completed NCT00070187 Phase 2, Phase 3 carmustine;cyclosporine;cytarabine;etoposide;melphalan
41 First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
42 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of the Sintilimab Plus ICE Regimen Versus Placebo Plus ICE Regimen in the Classic Hodgkin's Lymphoma Patients With First-line Standard Chemotherapy Failure Recruiting NCT04044222 Phase 3 Carboplatin;Etoposide;Ifosfamide;Placebo;Carboplatin;Etoposide;Ifosfamide
43 HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD Recruiting NCT02661503 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Brentuximab Vedotin;Dacarbazine;Dexamethasone
44 Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease Recruiting NCT01951885 Phase 3 tacrolimus;methotrexate;Mycophenolate mofetil;Methotrexate (low dose)
45 European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Recruiting NCT02684708 Phase 3 cyclophosphamide, vincristine, prednisone, dacarbazine;cyclo, vcr, pred, dacarb,etop and doxo
46 A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL). Recruiting NCT03159897 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
47 A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Recruiting NCT03907488 Phase 3 Brentuximab Vedotin;Dacarbazine;Doxorubicin;Doxorubicin Hydrochloride;Vinblastine;Vinblastine Sulfate
48 HD18 for Advanced Stages in Hodgkins Lymphoma Active, not recruiting NCT00515554 Phase 3 Rituximab;BEACOPP escalated
49 HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET Active, not recruiting NCT00736320 Phase 3 ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)
50 Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812) Active, not recruiting NCT03138499 Phase 3

Search NIH Clinical Center for Hodgkin's Paragranuloma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Genetic Tests for Hodgkin's Paragranuloma

Anatomical Context for Hodgkin's Paragranuloma

MalaCards organs/tissues related to Hodgkin's Paragranuloma:

40
T Cells, B Cells, Bone, Bone Marrow, Lung, Breast, Brain

Publications for Hodgkin's Paragranuloma

Articles related to Hodgkin's Paragranuloma:

(show all 14)
# Title Authors PMID Year
1
T-cell-rich B-cell lymphoma--a distinct clinicopathologic entity? 61
9021681 1996
2
How to differentiate between T-cell-rich B-cell lymphoma and lymphocyte-predominant Hodgkin's disease. Evidence for the value of MB1 and 4KB5 immunostaining. 61
8758204 1996
3
[Nodular paragranuloma (Hodgkin's disease) of the tonsil]. 61
9065241 1996
4
T-cell-rich B-cell lymphoma and lymphocyte-predominant Hodgkin's disease: two closely related entities? 61
7794762 1995
5
[Attempted classification of Hodgkin's paragranuloma]. 61
4293334 1967
6
[A case of orbital lymphoma (Hodgkin's paragranuloma)]. 61
5624057 1967
7
[CASE OF HODGKIN'S PARAGRANULOMA WITH DEATH CAUSED BY ILEAL PERFORATION]. 61
14060542 1963
8
The "benign" form of Hodgkin's disease (Hodgkin's paragranuloma). 61
13846056 1960
9
Generalized cytomegalic inclusion-body disease associated with pneumocystis pneumonia in adults. A report of three cases. with Wegener's granulomatosis. thrombotic purpura, and Hodgkin's disease as predisposing conditions. 61
13836212 1960
10
[Osseous lesions during Hodgkin's paragranuloma]. 61
14428765 1960
11
Hodgkin's paragranuloma. 61
13356263 1956
12
Hodgkin's paragranuloma masked by Friedlander's pneumonia; report of a case. 61
14384055 1955
13
Benign Hodgkin's disease (Hodgkin's paragranuloma). 61
12981613 1952
14
Hodgkin's disease; a clinical-pathological review of 150 cases. 61
18109362 1949

Variations for Hodgkin's Paragranuloma

Expression for Hodgkin's Paragranuloma

Search GEO for disease gene expression data for Hodgkin's Paragranuloma.

Pathways for Hodgkin's Paragranuloma

GO Terms for Hodgkin's Paragranuloma

Sources for Hodgkin's Paragranuloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....